Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 46

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 46
---
 agreement, we agreed to issue Xylo 2,208 units, or the Xylo Units
at a subscription price of CAD$720.00 (approximately $570.00) per Xylo Unit. Each Xylo Unit is comprised of one common share and one warrant
to purchase one common share. Each warrant will be exercisable for a period of 18 months into one additional common share at a price per
share of CAD$1,800.00. The transaction closed in April 2022.

<div align='center'>II-1</div>

On January 16, 2024, we consummated
a registered direct offering of 1,468,000 common shares and 32,000 pre-funded warrants at a price of $1.60 per common share and $1.5999
per pre-funded warrant share and a simultaneous private placement of unregistered common warrants to purchase an aggregate of up to 1,500,000
common shares. The unregistered common warrants have an exercise price of $1.60 per share, are immediately exercisable and have a 5-year
term from the issuance date.

On September 17, 2025, we
entered into securities purchase agreements, or the SPAs, with certain institutional investor parties that are named as selling shareholders
in the registration statement to which this prospectus relates, or the CLA Investors. Pursuant to the SPAs, we shall issue and sell to
the CLA Investors, convertible promissory notes, or the Promissory Notes, in the aggregate principal amount of $10,000,000, or the Subscription
Amount, for an aggregate purchase price of $9,000,000 (90% of the Subscription Amount). Upon the signing of the SPAs on September 17,
2025, the CLA Investors purchased from us Promissory Notes in the aggregate principal amount of $555,556, for a purchase price of $500,000.
Subject to the conditions in the SPAs, on the date on which the registration statement pursuant to which this prospectus relates is declared
effective by the Securities and Exchange Commission, or the Effective Date, we shall issue and sell to the CLA Investors additional Promissory
Notes in the aggregate principal amount of $1,944,444, for a purchase price of $1,750,000. Commencing on the date that is three months
after the Effective Date, we may request, at our sole discretion,